Related Experiment Video
Updated: May 10, 2026

07:07
Tumor Hypoxia Assessment: In Vivo 3D Oxygen Imaging Through Electron Paramagnetic Resonance
Published on: February 14, 2025
Modelling the interplay between hypoxia and proliferation in radiotherapy tumour response
J Jeong1, K I Shoghi, J O Deasy
1Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Physics in Medicine and Biology
|June 22, 2013
Summary
A new computational model simulates radiotherapy, revealing that conventional fraction sizes improve tumor control by accounting for hypoxia and proliferation. This model helps predict treatment outcomes and optimize radiation doses.
Area of Science:
- Radiotherapy
- Computational modeling
- Tumor biology
Background:
- Fractionated radiotherapy efficacy depends on tumor microenvironment factors like hypoxia and proliferation.
- Understanding the interplay of these factors is crucial for optimizing treatment outcomes.
Purpose of the Study:
- To develop a computational model simulating tumor control probability during fractionated radiotherapy.
- To incorporate hypoxia, proliferation, and reoxygenation dynamics.
- To evaluate the impact of varying growth fraction (GF) and volume doubling time (TD) on treatment outcomes.
Main Methods:
- A three-compartment model was developed: proliferating, intermediate (metabolically-active), and hypoxic.
- Initial cell distribution was determined by local GF and TD.
- Tumor response simulations were performed for head and neck squamous cell carcinoma.
Main Results:
- Conventional fraction sizes (2-2.4 Gy) predicted smaller tumor control dose 50% (TCD50) values than larger fractions (4-5 Gy) due to reoxygenation.
- Increased initial proliferation (high GF) surprisingly led to moderately higher local control.
- Tumor hypoxia was predicted to increase the required dose for local control by approximately 30%.
Conclusions:
- The model uniquely determines initial cell distribution from GF and TD.
- It demonstrates how local resource competition impacts local control rates under varying fractionation.
- Predicted tumor regression patterns align with clinical observations.
Related Concept Videos
Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...

